Dear Ms. Benassou:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received February 8, 2011, submitted under 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tyzeka® (telbivudine) 600 mg tablets and Tyzeka® (telbivudine) oral solution 100 mg/5 mL.

We acknowledge receipt of your amendments dated February 24, 2011 and March 14, 2011.

We also refer to our letter dated November 19, 2010, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Tyzeka® (telbivudine) 600 mg tablets and Tyzeka® (telbivudine) oral solution 100 mg/5 mL. This information pertains to the higher risk of development of resistance-associated substitutions in treated patients. We also acknowledge receipt of your December 17, 2010, response to this request.

These supplemental new drug applications provide for revisions to the labeling for Tyzeka® (telbivudine), consistent with the agreed upon changes to the language included in our November 19, 2010, letter are as follows (additions are noted by underline and deletion are noted by strikethrough). In addition, to avoid medication errors, all \( \leq \) or \( \geq \) symbols have been spelled out throughout the package insert (PI).

Indications and Usage—Under Section 1.1 Chronic Hepatitis B, “The following points should be considered when initiating therapy with Tyzeka”:

- For HBeAg-positive patients, Tyzeka should only be initiated in patients with HBV DNA less than 9 \( \log_{10} \) copies/mL and ALT greater than or equal to 2x Upper Limit of Normal (ULN) prior to treatment.
- For HBeAg-negative patients, Tyzeka should only be initiated in patients with HBV DNA less than 7 \( \log_{10} \) copies/mL prior to treatment.
- On-treatment response should guide continued therapy [see Dosage and Administration (2.1) and Microbiology (12.4)].
Dosage and Administration-Under Section 2.1 Adults and Adolescents (≥16 years of age and older):

Due to higher rates of resistance that may develop with longer term treatment among patients with incomplete viral suppression, treatment should only be initiated, if pre-treatment HBV DNA and ALT measurements are known, in the following patient populations:

For HBeAg-positive patients, HBV DNA should be less than \(9 \log_{10} \text{ copies/mL}\) and ALT should be greater than or equal to \(2 \times \text{ULN}\) prior to treatment with Tyzeka.

For HBeAg-negative patients, HBV DNA should be less than \(7 \log_{10} \text{ copies/mL}\) prior to treatment with Tyzeka.

HBV DNA levels should be monitored at 24 weeks of treatment to assure complete viral suppression (HBV DNA less than 300 copies/mL). Alternate therapy should be initiated for patients who have detectable HBV DNA after 24 weeks of treatment. Optimal therapy should be guided by further resistance testing.

Dosage and Administration-Under Section 2.4-Duration of Therapy:

For patients with incomplete viral suppression (HBV DNA greater than or equal to 300 copies/mL) after 24 weeks of treatment, alternate therapy should be instituted. HBV DNA should be monitored every 6 months to assure continued response. If patients test positive for HBV DNA at any time after their initial response, alternate treatment should be instituted. Optimal therapy should be guided by resistance testing.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling.
[21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/der.html](http://www.fda.gov/opacom/morechoices/fdaforms/der.html); instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacey Min, Pharm.D., Regulatory Project Manager, at (301) 796-4253.

Reference ID: 2924807
Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
03/29/2011